Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Endocrinology
•
Hypertension
•
Diabetes
Is azilsartan superior to other angiotension receptor blockers in regard to cardiorenal outcome data?
Related Questions
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
When should you consider adding clonidine to an antihypertensive regimen for patients with advanced CKD?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Besides treadmill, what other exercises may be considered for post-exercise ABIs, and are their diagnostic parameters identical to standard post-exercise ABIs?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?
Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?
Is it a good practice to prescribe clonidine to take as needed for occasional severe blood pressure elevations?
What is your systolic blood pressure target for patients over 80 with frailty and multiple comorbidities?
How do you titrate the dose of an ACE inhibitor in a patient with type 1 diabetes mellitus who is normotensive but has moderately increased albuminuria?
